Compare Nuwellis Inc (NUWE) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while Direxion Daily FTSE China Bull 3x Shares trades at $25.22 (market cap $560.32M). The key difference: Direxion Daily FTSE China Bull 3x Shares is far larger — about 254.7× Nuwellis Inc's market cap, and Direxion Daily FTSE China Bull 3x Shares is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Direxion Daily FTSE China Bull 3x Shares for 25 Days on average.
| NUWE | YINN | |
|---|---|---|
Market Cap | $2.20M | $560.32M |
Volume | 121,544 | 1,009,521 |
Sector | Health | Leveraged / Inverse |
52-Week High | $146.65 | $52.69 |
52-Week Low | $0.68 | $21.45 |
Typical Hold Time | 26 Days | 25 Days |
Enterprise Value | -$1.52M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
YINN trades at $25.17, up 6.83% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock lacks fundamental financial data disclosure, with key valuation and profitability ratios unavailable. Recent news highlights China's economic policies and export controls, which may influence the fund's underlying holdings.
The outlook is cautious due to bearish technicals and opaque fundamentals. Risks include exposure to Chinese market volatility and regulatory changes. Analyst sentiment is not clearly defined without current consensus data, requiring careful monitoring of emerging financial disclosures and geopolitical developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
